Monocyte mimics improve mesenchymal stem cell-derived extracellular vesicle homing in a mouse MI/RI model

Zhang, Ning; Song, Yanan; Huang, Zheyong; Chen, Jing; Tan, Haipeng; Yang, Hongbo; Fan, Mengkang; Li, Qiyu; Wang, Qiaozi; Gao, Jiantou; Pang, Zhiqing; Qian, Juying

doi:10.1016/j.biomaterials.2020.120168

Cited by 95 publications

(93 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To reduce off-target delivery, engineered exosomes and prior blocking of endocytosis of exosomes by macrophages have been utilized to enhance the delivery efficiency of exosomes to specific cells, offering therapeutic benefit [ 114 – 116 ]. Thus, these have improved delivery efficiency, including platelet nanovesicles [ 117 ], monocyte mimic–modified EVs [ 118 ], EVs incorporated in alginate hydrogel [ 119 ], overexpressed targeting sequences or those modified by DMPE-PEG-streptavidin (DPS), and biotin-conjugated antibody or peptide.…”

Section: Targeting the Therapeutic Role Of Macrophages Post-mimentioning

confidence: 99%

New Insights and Novel Therapeutic Potentials for Macrophages in Myocardial Infarction

et al. 2021

View full text Add to dashboard Cite

Cardiovascular disease (CVD) has long been the leading cause of death worldwide, and myocardial infarction (MI) accounts for the greatest proportion of CVD. Recent research has revealed that inflammation plays a major role in the pathogenesis of CVD and other manifestations of atherosclerosis. Overwhelming evidence supports the view that macrophages, as the basic cell component of the innate immune system, play a pivotal role in atherosclerosis initiation and progression. Limited but indispensable resident macrophages have been detected in the healthy heart; however, the number of cardiac macrophages significantly increases during cardiac injury. In the early period of initial cardiac damage (e.g., MI), numerous classically activated macrophages (M1) originating from the bone marrow and spleen are rapidly recruited to damaged sites, where they are responsible for cardiac remodeling. After the inflammatory stage, the macrophages shift toward an alternatively activated phenotype (M2) that promotes cardiac repair. In addition, extensive studies have shown the therapeutic potential of macrophages as targets, especially for emerging nanoparticle-mediated drug delivery systems. In the present review, we focused on the role of macrophages in the development and progression of MI, factors regulating macrophage activation and function, and the therapeutic potential of macrophages in MI.

show abstract

Section: Targeting the Therapeutic Role Of Macrophages Post-mimentioning

confidence: 99%

New Insights and Novel Therapeutic Potentials for Macrophages in Myocardial Infarction

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In addition, even though EVs have demonstrated similar effects to MSCs, their homing ability is much weaker than that of MSCs, representing a limitation of MSC-EV-based therapy that needs improving. Zhang et al recently used monocyte mimics to enhance the homing ability of MSC-EVs to the injured site in a myocardial IRI model, suggesting a possible approach for improving the homing ability of MSC-EVs for the therapy of AKI (140). Regarding monitoring the distribution of EVs, their physicochemical properties may be affected by some lipophilic markers, which could affect the observations (13), and new tracing markers will be needed to detect the distribution and effects of EVs in clinical practice.…”

Section: Limitations and Future Perspectives Of Msc-evsmentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Potential Therapeutic Strategy for Acute Kidney Injury

Yang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Acute kidney injury (AKI) is a common and potential life-threatening disease in patients admitted to hospital, affecting 10%–15% of all hospitalizations and around 50% of patients in the intensive care unit. Severe, recurrent, and uncontrolled AKI may progress to chronic kidney disease or end-stage renal disease. AKI thus requires more efficient, specific therapies, rather than just supportive therapy. Mesenchymal stem cells (MSCs) are considered to be promising cells for cellular therapy because of their ease of harvesting, low immunogenicity, and ability to expand in vitro. Recent research indicated that the main therapeutic effects of MSCs were mediated by MSC-derived extracellular vesicles (MSC-EVs). Furthermore, compared with MSCs, MSC-EVs have lower immunogenicity, easier storage, no tumorigenesis, and the potential to be artificially modified. We reviewed the therapeutic mechanism of MSCs and MSC-EVs in AKI, and considered recent research on how to improve the efficacy of MSC-EVs in AKI. We also summarized and analyzed the potential and limitations of EVs for the treatment of AKI to provide ideas for future clinical trials and the clinical application of MSC-EVs in AKI.

show abstract

“…MSC-derived EV modulate monocyte phenotypes in a model of airway inflammation from a classical/inflammatory phenotype to a non-classical anti-inflammatory phenotype [65,66] and under hypoxic conditions MSC-derived EV regulate macrophage anti-inflammatory phenotype via EV miR-21-5p and promote lung cancer development [66]. MSC-derived EV fused with monocyte-derived EV show enhanced propensity to accumulate in the injured heart following myocardial infarction, induce endothelial cell maturation during angiogenesis and impact macrophage phenotypes [67].…”

Section: Figure 3 the Crosstalk Between Monocytes And Macrophages Through The Generation And Release Of Extracellular Vesicles (Ev)mentioning

confidence: 99%

Extracellular Vesicles in Innate Immune Cell Programming

2021

View full text Add to dashboard Cite

Extracellular vesicles (EV) are a heterogeneous group of bilipid-enclosed envelopes that carry proteins, metabolites, RNA, DNA and lipids from their parent cell of origin. They mediate cellular communication to other cells in local tissue microenvironments and across organ systems. EV size, number and their biologically active cargo are often altered in response to pathological processes, including infection, cancer, cardiovascular diseases and in response to metabolic perturbations such as obesity and diabetes, which also have a strong inflammatory component. Here, we discuss the broad repertoire of EV produced by neutrophils, monocytes, macrophages, their precursor hematopoietic stem cells and discuss their effects on the innate immune system. We seek to understand the immunomodulatory properties of EV in cellular programming, which impacts innate immune cell differentiation and function. We further explore the possibilities of using EV as immune targeting vectors, for the modulation of the innate immune response, e.g., for tissue preservation during sterile injury such as myocardial infarction or to promote tissue resolution of inflammation and potentially tissue regeneration and repair.

show abstract

Monocyte mimics improve mesenchymal stem cell-derived extracellular vesicle homing in a mouse MI/RI model

Cited by 95 publications

References 33 publications

New Insights and Novel Therapeutic Potentials for Macrophages in Myocardial Infarction

New Insights and Novel Therapeutic Potentials for Macrophages in Myocardial Infarction

Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Potential Therapeutic Strategy for Acute Kidney Injury

Extracellular Vesicles in Innate Immune Cell Programming

Contact Info

Product

Resources

About